Search - tctmd.com

Displaying 1 - 20 of 34

Sort: Relevancy | Date

News Daily News

Extreme Alcohol Intake Directly Damages the Heart, Study Confirms

Caitlin E. Cox

December 24, 2019

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Daily News

Grief and CVD: Simple Regimen May Lower Risk

L.A. McKeown

November 19, 2019

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Todd Neale

November 18, 2019

News Conference News AHA 2019

No Benefit of Colchicine in All-Comers PCI

Shelley Wood

November 17, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Industry News

Intact Vascular Announces Positive Six-Month Data from TOBA II BTK Clinical Trial During Late-Breaking Session at 2019 VIVA Conference

November 06, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

News Industry News

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

September 27, 2019

News Conference News HFSA 2019

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

L.A. McKeown

September 24, 2019

News Daily News

Greater Exposure to Toxins on 9/11 Left Firefighters at Increased Long-term CVD Risk

L.A. McKeown

September 11, 2019

News Daily News

Endurance Training and A-fib: Relationship Differs by Sex

Todd Neale

August 29, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Daily News

PET May Be Able to Pinpoint PAD Patients at Risk of Restenosis

Caitlin E. Cox

August 15, 2019

News Industry News

2nd ‘Breakthrough Device Designation’ granted to Concept Medical Inc. by FDA for MagicTouch PTA Sirolimus Coated Balloon

August 13, 2019

News Daily News

Higher Risk of Atrial Fibrillation in Retired Football Players

Michael O'Riordan

July 25, 2019

News Industry News

FDA approves Bayer's Gadavist® (gadobutrol) injection as the first and only contrast agent for use in cardiac MR in adult patients with known or suspected coronary artery disease

July 15, 2019

News Conference News SCCT 2019

Sex-Specific ‘Inventory’ Needed to Spot Key CVD Risk Factors in Women

Yael L. Maxwell

July 12, 2019

News Daily News

Exposure to Air Pollution in China Tied to Increase in Coronary Calcium

Todd Neale

June 28, 2019

Advertisement

Extreme Alcohol Intake Directly Damages the Heart, Study Confirms

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Grief and CVD: Simple Regimen May Lower Risk

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

No Benefit of Colchicine in All-Comers PCI

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Intact Vascular Announces Positive Six-Month Data from TOBA II BTK Clinical Trial During Late-Breaking Session at 2019 VIVA Conference

Recurrent Events Common Among Young Patients With CAD

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

Greater Exposure to Toxins on 9/11 Left Firefighters at Increased Long-term CVD Risk

Endurance Training and A-fib: Relationship Differs by Sex

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

PET May Be Able to Pinpoint PAD Patients at Risk of Restenosis

2nd ‘Breakthrough Device Designation’ granted to Concept Medical Inc. by FDA for MagicTouch PTA Sirolimus Coated Balloon

Higher Risk of Atrial Fibrillation in Retired Football Players

FDA approves Bayer's Gadavist® (gadobutrol) injection as the first and only contrast agent for use in cardiac MR in adult patients with known or suspected coronary artery disease

Sex-Specific ‘Inventory’ Needed to Spot Key CVD Risk Factors in Women

Exposure to Air Pollution in China Tied to Increase in Coronary Calcium

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content